From BODE to ADO to outcomes in multimorbid COPD patients

The Lancet

Volumn 374, Issue 9691, 2009, Pages 667-668

  Schünemann, Holger ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL;

AGE DYSPNEA AIRFLOW OBSTRUCTION; ARTICLE; BLOOD PRESSURE; BODY MASS INDEX AIRFLOW OBSTRUCTION DYSPNEA EXERCISE CAPACITY; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CONGESTIVE HEART FAILURE; DATA BASE; DISEASE SEVERITY; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; LAW; MANAGEMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MORTALITY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; SPAIN; SWITZERLAND;

EID: 69149096454     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61539-7     Document Type: Note

References (7)

1. WHO. 2008-2013 action plan for the global strategy for the prevention and control of non communicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases, diabetes (2008). http://www.who.int/nmh/publications/ncd_action_plan_en.pdf (accessed Aug 18, 2009).
2. Puhan M.A., Garcia-Aymerich J., Frey M., et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 374 (2009) 704-711
3. Nannini L.J., Cates C.J., Lasserson T.J., and Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4 (2007) CD006826.
4. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007) 250-255
5. Dahl M., Bowler R.P., Juul K., Crapo J.D., Levy S., and Nordestgaard B.G. Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations. Am J Respir Crit Care Med 178 (2008) 906-912
6. Schunemann H.J., Woodhead M., Anzueto A., et al. A vision statement on guideline development for respiratory disease: the example of COPD. Lancet 373 (2009) 774-779
7. Schunemann H.J., Oxman A.D., Brozek J., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 (2008) 1106-1110